| Assessment Status | Rapid Review Complete |
| HTA ID | 25026 |
| Drug | Avapritinib |
| Brand | Ayvakyt® |
| Indication | Avapritinib is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. |
| Assessment Process | |
| Rapid review commissioned | 24/03/2025 |
| Rapid review completed | 17/04/2025 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avapritinib compared with the current standard of care. |
